行情

NBIX

NBIX

神经分泌生物科学
NASDAQ

实时行情|Nasdaq Last Sale

113.75
-3.06
-2.62%
已收盘, 18:55 12/09 EST
开盘
117.47
昨收
116.81
最高
118.00
最低
113.58
成交量
90.70万
成交额
--
52周最高
119.65
52周最低
64.72
市值
104.76亿
市盈率(TTM)
673.48
分时
5日
1月
3月
1年
5年

分析师评级

19位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

NBIX 新闻

  • Xenon Pharmaceuticals Provides Updates on Partnered Neurology Pipeline Programs at AES 2019
  • Benzinga.2天前
  • Xenon Pharmaceuticals Provides Updates on Partnered Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting
  • GlobeNewswire.2天前
  • With EPS Growth And More, Neurocrine Biosciences (NASDAQ:NBIX) Is Interesting
  • Simply Wall St..3天前
  • Neurocrine Partners With Xenon To Add New Early-Stage Pipeline Assets
  • Seeking Alpha - Article.4天前

更多

所属板块

生物技术和医学研究
+0.51%
制药与医学研究
+0.23%

热门股票

名称
价格
涨跌幅

NBIX 简况

Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson's disease. Its product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems.
展开

Webull提供Neurocrine Biosciences, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。